The Quantellect read.As of Nov 19, 2026, 11 active firms cover Krystal Biotech Inc: 10 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $284.00 to $441.00, a moderate spread. The average target of $366.90 sits 16% above the current $315.33. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.08 next quarter toward $9.23 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 active firms
Buy
Strong Buy00%
Buy1091%
Neutral19%
Sell00%
Strong Sell00%
Based on 11 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$366.90
+16.4% upside
Average target across 10 active firms as of Nov 19, 2026 vs $315.33 current
Highest Target$441.00
Average Target$366.90
Lowest Target$284.00
Detailed analyst forecasts for KRYS
Showing 1–12 of 12 named analysts shown · 11 active firms in the rating projection
As of Nov 19, 2026, 10 of 11 active firms rate KRYS a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
KRYS EPS & revenue forecast
EPS · NEXT QUARTER
$2.08
Range $1.80 – $2.52 · 4 analysts · +14% YoY
Next period, 4 analysts expect Krystal Biotech Inc to earn $2.08 a share (range $1.80 – $2.52), versus $1.83 a year earlier. Full-year consensus is $8.01, growing to $9.23 the year after.
REVENUE · NEXT QUARTER
$139.4M
Range $134.4M – $144.1M · 4 analysts · +20% YoY
Revenue is expected to reach $139.4M (range $134.4M – $144.1M), +19.8% year-over-year. Full-year consensus is $497.5M, rising to $634.9M next year.
Top analysts covering Krystal Biotech Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KRYS.
#1
Geulah Livshits
Chardan Capital · Rank #104
Buy
$323.00+2.4% to target
Overall win rate
43%
+ Follow
#2
Roger Song
Jefferies · Rank #122
Buy
$474.00+50.3% to target
Overall win rate
43%
+ Follow
#3
Debjit Chattopadhyay
Guggenheim · Rank #248
Buy
$284.00-9.9% to target
Overall win rate
39%
+ Follow
#4
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Buy
$361.00+14.5% to target
Overall win rate
34%
+ Follow
#5
Yigal Nochomovitz
Citigroup · Rank #381
Buy
$386.00+22.4% to target
Overall win rate
38%
+ Follow
KRYS stock forecast FAQ
What is KRYS's average 12-month price target?+
The 10 active firms with a live target average $366.90 for Krystal Biotech Inc over the next 12 months, ranging from a $441.00 high to a $284.00 low, as of Nov 19, 2026.
Is KRYS stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 11 active firms as of Nov 19, 2026, 10 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for KRYS?+
The Street-high target is $441.00 (Goldman Sachs), and the Street-low is $284.00 (Guggenheim). The average of all 10 active-firm targets is $366.90.
How many active Wall Street firms cover KRYS?+
11 active firms have a recognized rating on Krystal Biotech Inc as of Nov 19, 2026, and 10 active firms carry a live 12-month price target.
Who is the most accurate analyst covering KRYS?+
Among analysts who currently cover KRYS, Geulah Livshits of Chardan Capital has the strongest overall Quantellect track record (Rank #104). Their current call is Buy with a $323.00 target.
What is Krystal Biotech Inc's projected EPS for next quarter?+
The consensus estimate is $2.08 per share (range $1.80 – $2.52) across 4 analysts. Full-year EPS is projected at $8.01, rising to $9.23 the following year.
How much revenue is Krystal Biotech Inc expected to report next quarter?+
Consensus revenue is $139.4M (range $134.4M – $144.1M). Full-year revenue is projected at $497.5M, growing to $634.9M next year.
Have analysts been upgrading or downgrading KRYS lately?+
As of Nov 19, 2026, 10 of 11 active firms rate KRYS a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KRYS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.